Family PlanningPhase 4NCT02714231
Oral Diclofenac Sodium Versus Oral Hyoscine Butyl Bromide During Intrauterine Device Insertion
A Phase 4 study testing diclofenac sodium (cataflam) and hyoscine butyl bromide (buscopan) in people with Family Planning, run by Assiut University at 1 site in Egypt.
Trial summary
The aim of our study is to compare the analgesic effect of oral diclofenac sodium versus oral hyoscine butyl bromide during intrauterine device insertion. Read more about this study
- Who is it for?
- Ages 20 to 50 years, women only
- Conditions the study is for
- Family Planning
- What is being tested?
- diclofenac sodium (cataflam) and hyoscine butyl bromide (buscopan)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- Mar 2016to Mar 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women not taken analgesics or anxiolytics in the 24 hours prior insertion
- Women not taken misoprostol prior to intrauterine device insertion
- Women who will accept to participate in the study
Who cannot join
- Any contraindication to intrauterine device placement
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized Controlled Trial of 2 Different Methods for Pain Relief During Intrauterine Device Insertion
The aim of our study is to compare the analgesic effect of oral diclofenac sodium versus oral hyoscine butyl bromide during intrauterine device insertion.
- Conditions
- Family Planning
- Being tested
- diclofenac sodium (cataflam), hyoscine butyl bromide (buscopan)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
diclofenac sodium (cataflam)Drug
The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
hyoscine butyl bromide (buscopan)Drug
The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
| Study group | Role | What they receive |
|---|---|---|
| diclofenac | Experimental | oral diclofuhenac sodium Receives: Drug: diclofenac sodium (cataflam) |
| hyoscine | Active comparator | oral hyoscine butyl bromide Receives: Drug: hyoscine butyl bromide (buscopan) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean pain score during insertion
Measured: intraoperative
Secondary outcomes (1)
Patient satisfaction score
Measured: 5 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2016 (estimated)
- Study startMar 2016
- Primary completionFeb 2017
- Study completionMar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Family PlanningStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Mohamed Abbas, Assiut University
- Investigators
- ahmed abbas, MD, Principal investigator, Woman health hospital Assiut
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02714231
- Sponsor's protocol ID
- DS-HB
- Status last verified
- Jul 2017
- First submitted
- 14 Mar 2016
- Last updated
- 19 Jul 2017
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of 2 Different Methods for Pain Relief During Intrauterine Device Insertion
- ClinicalTrials.gov ID
- NCT02714231
- Acronym / sponsor ID
- DS-HB
- Conditions
- Family Planning
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Mar 2016
- Primary completion
- Feb 2017 (actual)
- Study completion
- Mar 2017 (actual)
- First posted
- 21 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our study is to compare the analgesic effect of oral diclofenac sodium versus oral hyoscine butyl bromide during intrauterine device insertion.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| diclofenac | Experimental | Drug: diclofenac sodium (cataflam)oral diclofuhenac sodium |
| hyoscine | Active comparator | Drug: hyoscine butyl bromide (buscopan)oral hyoscine butyl bromide |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Women not taken analgesics or anxiolytics in the 24 hours prior insertion
- Women not taken misoprostol prior to intrauterine device insertion
- Women who will accept to participate in the study
Key exclusion criteria (1 listed)
- Any contraindication to intrauterine device placement
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| diclofenac sodium (cataflam)The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure | Drug | diclofenac |
| hyoscine butyl bromide (buscopan)The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure | Drug | hyoscine |
Primary outcome
Mean pain score during insertion
Time frame: intraoperative
1 secondary outcome
Patient satisfaction score
Time frame: 5 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2017.
- Individual participant dataSharing planned: Yes
Related trials for Family Planning
Recruiting
Estimating the Impact of Sexuality Education and Mobile Health Services on Reproductive Health and Empowerment Among Adolescents in Sierra Leone for the Family Planning Impact Lab
Reproductive Health, Sexual Health
Not yet recruiting
Impact of Gender-Transformative Interventions on Contraceptive Use and Reproductive Autonomy in Somalia
Contraceptive Behavior, Social Norms
Recruiting
Impact of Self-Care Family Planning Services on Health and Development in South Sudan (Family Planning Impact Lab)
Contraceptive Behavior, Self Administration
Recruiting
Improving Women's Fertility Awareness and Reducing Anxiety Through Ovarian Reserve Screening and AI Counseling
Fertility Awareness, Ovarian Reserve
Active, not recruiting
Future Planning and Well-Being for Individuals With Intellectual Disabilities and Family Caregivers
Intellectual Disability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ahmed abbas, MD principal investigator
Woman health hospital Assiut
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing diclofenac sodium (cataflam) and hyoscine butyl bromide (buscopan) in people with Family Planning, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean pain score during insertion (time frame: intraoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2017.